Judge halts Royalty Pharma's bid for Elan stock

by The Associated Press

Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the company.

Royalty is a privately held New York company that buys royalty interests in drugs and late-stage . It made an offer to buy Elan last month for $12.50 per share, or about $7.5 billion. Its offer was conditioned on shareholders rejecting an Elan push to refocus its business after selling its interest in the blockbuster multiple sclerosis treatment .

Elan has said the Royalty offer, which is scheduled to expire Thursday, undervalues Elan and is not in shareholders' best interests. It also has accused Royalty of deliberately misleading shareholders about the value of the Tysabri deal.

A Royalty Pharma representative declined to comment on that accusation.

Elan also announced Tuesday that Royalty has agreed not to distribute its proxy statement to Elan shareholders until regulators in Ireland can review it.

Elan sold its interest in Tysabri to former development partner Biogen Idec Inc. for $3.25 billion in cash and recurring .

Royalty has said its offer represented a "compelling value" of $4.6 billion for Elan's Tysabri royalty, and it said Elan sold about half its rights in Tysabri to Biogen.

But Elan countered that it has never suggested that the $3.25 billion upfront payment represented half of its rights, and such an assumption was a simple attempt to overstate the premium Royalty's offer provides.

Elan recently announced a push to diversify. It will pay about $338 million for a privately held Austrian drug developer and at least $110 million for stakes in two other companies. The company also will pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and as part of a push to diversify.

Royalty also had offered in February to buy Elan for $11 per share and later raised that bid to $11.25 per share.

U.S.-traded shares of Elan Corp. PLC climbed 10 cents to close at $12.57. Elan's share price has climbed about 8 percent since May 17, the last trading day before Royalty made its latest offer.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Elan moves to deter takeover bid

Mar 04, 2013

(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.

Elan enters $1B royalty deal with Theravance

May 13, 2013

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

US approves new multiple sclerosis capsules

Mar 27, 2013

The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.